FibroGen (FGEN) Competitors $11.18 +0.09 (+0.81%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$11.14 -0.04 (-0.40%) As of 08/22/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. SLS, TVGN, ENTA, CRBU, LFVN, ACTU, NKTX, NVCT, LXEO, and CYBNShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include SELLAS Life Sciences Group (SLS), Tevogen Bio (TVGN), Enanta Pharmaceuticals (ENTA), Caribou Biosciences (CRBU), Lifevantage (LFVN), Actuate Therapeutics (ACTU), Nkarta (NKTX), Nuvectis Pharma (NVCT), Lexeo Therapeutics (LXEO), and Cybin (CYBN). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Its Competitors SELLAS Life Sciences Group Tevogen Bio Enanta Pharmaceuticals Caribou Biosciences Lifevantage Actuate Therapeutics Nkarta Nuvectis Pharma Lexeo Therapeutics Cybin FibroGen (NASDAQ:FGEN) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Do analysts prefer FGEN or SLS? FibroGen presently has a consensus price target of $43.00, indicating a potential upside of 284.62%. SELLAS Life Sciences Group has a consensus price target of $7.00, indicating a potential upside of 266.49%. Given FibroGen's higher possible upside, analysts clearly believe FibroGen is more favorable than SELLAS Life Sciences Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is FGEN or SLS more profitable? SELLAS Life Sciences Group has a net margin of 0.00% compared to FibroGen's net margin of -3.86%. FibroGen's return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets FibroGen-3.86% N/A -27.34% SELLAS Life Sciences Group N/A -132.51%-92.79% Which has more risk & volatility, FGEN or SLS? FibroGen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Do insiders and institutionals hold more shares of FGEN or SLS? 72.7% of FibroGen shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 3.1% of FibroGen shares are owned by insiders. Comparatively, 1.4% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings & valuation, FGEN or SLS? SELLAS Life Sciences Group has lower revenue, but higher earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroGen$29.62M1.52-$47.58M-$0.38-29.42SELLAS Life Sciences GroupN/AN/A-$30.88M-$0.32-5.97 Does the media favor FGEN or SLS? In the previous week, FibroGen had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 5 mentions for FibroGen and 4 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.81 beat FibroGen's score of -0.01 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroGen 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryFibroGen and SELLAS Life Sciences Group tied by winning 7 of the 14 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.85M$2.54B$5.75B$9.61BDividend YieldN/A1.67%4.41%4.10%P/E Ratio-29.4222.6131.2226.05Price / Sales1.52555.43434.78103.68Price / CashN/A180.4637.7358.48Price / Book-0.225.939.536.61Net Income-$47.58M$31.83M$3.26B$265.65M7 Day Performance17.81%1.89%2.14%2.03%1 Month Performance48.08%1.33%2.83%-0.30%1 Year Performance11.22%8.84%30.64%19.06% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen4.644 of 5 stars$11.18+0.8%$43.00+284.6%+15.8%$44.85M$29.62M-29.42570Gap UpSLSSELLAS Life Sciences Group2.8822 of 5 stars$1.73+6.1%$7.00+304.6%+45.8%$182.17M$1M-5.4110TVGNTevogen Bio3.9781 of 5 stars$0.96+1.6%$10.00+937.6%+55.8%$177.23MN/A0.003News CoverageEarnings ReportENTAEnanta Pharmaceuticals3.6327 of 5 stars$8.17+2.1%$21.67+165.2%-29.5%$174.68M$67.64M-1.89160CRBUCaribou Biosciences2.8616 of 5 stars$1.87-5.6%$6.67+256.5%-11.5%$174.13M$9.99M-1.05100LFVNLifevantage3.6986 of 5 stars$13.69+1.5%$30.50+122.8%+56.1%$172.36M$200.16M19.84260News CoveragePositive NewsUpcoming EarningsACTUActuate TherapeuticsN/A$8.25+1.6%$20.50+148.5%+3.9%$168.88MN/A0.0010News CoverageAnalyst DowngradeAnalyst RevisionNKTXNkarta2.0066 of 5 stars$2.35+0.9%$13.60+478.7%-54.0%$166.92MN/A-1.59140NVCTNuvectis Pharma3.6957 of 5 stars$6.45+0.3%$15.33+137.7%-4.6%$164.22MN/A-5.518Positive NewsLXEOLexeo Therapeutics2.351 of 5 stars$4.92+4.2%$15.33+211.7%-59.8%$163.34M$650K-1.5158Analyst RevisionCYBNCybin2.4327 of 5 stars$6.92-2.0%$85.00+1,128.3%N/A$163.24MN/A-1.5850News CoverageAnalyst Revision Related Companies and Tools Related Companies SELLAS Life Sciences Group Competitors Tevogen Bio Competitors Enanta Pharmaceuticals Competitors Caribou Biosciences Competitors Lifevantage Competitors Actuate Therapeutics Competitors Nkarta Competitors Nuvectis Pharma Competitors Lexeo Therapeutics Competitors Cybin Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access